Otsuka Pharmaceutical Co. Ltd., based in Japan, has established a presence in Australia with a new office in Sydney as part of an effort to build a larger, long-term presence in Australia and Oceania. These regions have been experiencing single-digit percentage growth in the past several years and were estimated at approximately $13 billion in 2012. Otsuka focuses on the development of new drugs for central nervous system disorders such as schizophrenia, depression and Alzheimer’s disease, area...